Eli Lilly and Company, Inc.
Eli Lilly and Company is a pharmaceutical company dedicated to discovering and developing innovative medicines. They are currently researching and developing orforglipron, an investigational oral GLP-1 medication for the treatment of type 2 diabetes and obesity. The company aims to bring this medicine to market pending regulatory approval, with plans to launch globally if approved.
Industries
biotechnology
health-care
medical
pharmaceutical
Nr. of Employees
Very Large (1000+)
Eli Lilly and Company, Inc.
Products
Investigational once-daily oral GLP-1 receptor agonist (oral small-molecule)
An investigational oral small-molecule GLP-1 receptor agonist developed as a once-daily pill formulation being studied for lowering blood glucose in type 2 diabetes and supporting weight loss in people with obesity or overweight. Studied in multiple clinical trials including late-stage (Phase 3) studies; not approved for clinical use.
Investigational once-daily oral GLP-1 receptor agonist (oral small-molecule)
An investigational oral small-molecule GLP-1 receptor agonist developed as a once-daily pill formulation being studied for lowering blood glucose in type 2 diabetes and supporting weight loss in people with obesity or overweight. Studied in multiple clinical trials including late-stage (Phase 3) studies; not approved for clinical use.
Expertise Areas
- Clinical development for type 2 diabetes and obesity
- Small-molecule therapeutic discovery and optimization
- Phase 1–3 trial execution and clinical evidence generation
- Regulatory submission strategy for metabolic indications
Key Technologies
- Oral small-molecule GLP-1 receptor agonist modality
- Phase 1–3 clinical trial platforms
- Oral formulation and dosing development
- Clinical data analysis and regulatory-grade evidence generation